Burosumab, sold under the brand name Crysvita, is a

human monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell Lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodies ca ...

medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.

Medical uses

In the European Union and the United States, burosumab is indicated for the treatment of adults and children ages one year and older with X-linked hypophosphatemia (XLH), a rare, inherited form of rickets. caused by overproduction of a hormone called FGF23 (fibroblast growth factor 23) in bone cells. FGF23 is responsible for blocking phosphate re-absorption in the kidney and the suppression of the vitamin D dependent phosphate absorption in the intestine. Due to the excess activity of FGF23, phosphate levels in the blood are abnormally low ( hypophosphatemia), which affects the constitution of bone. Thus, burosumab is designed to bind to the FGF23 receptor and inhibit the excess activity of the FGF23 hormone within the body. In the United States, burosumab is also approved to treat people age two and older with tumor-induced osteomalacia (TIO), a rare disease which is characterized by the development of tumors causing weakened and softened bones. The tumors associated with TIO release fibroblast growth factor 23 (FGF23) which lowers phosphate levels.

Legal status

It was approved for use in the European Union in February 2018 to treat children one year of age and older and adolescents with growing skeletons who have X-linked hypophosphataemia with radiographic evidence of bone disease . In April 2018, the U.S. Food and Drug Administration (FDA) approved burosumab for its intended purpose in patients aged one year and older. The FDA approval fell under both the breakthrough therapy and

orphan drug An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of ...

designations. The FDA considered it to be a first-in-class medication. In 2018, the National Institute for Health and Care Excellence in England and Wales raised concerns regarding the incremental

cost-effectiveness Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the relative costs and outcomes (effects) of different courses of action. Cost-effectiveness analysis is distinct from cost–benefit analysis, which assigns a monetar ...

of the new treatment but as of 2019 the drug was available through a simple discount scheme.

History

This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin.

References

External links

* {{Portal bar , Medicine Breakthrough therapy Monoclonal antibodies Orphan drugs Therapeutic antibodies